|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Cancer Society: Cancer facts and
figures 2007. Atlanta: American Cancer Society. 2007.
|
|
3
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L:
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions: The
IASLC Lung Cancer Staging Project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of Malignant Tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perez CA, Pajak TF, Rubin P, Simpson JR,
Mohiuddin M, Brady LW, Perez-Tamayo R and Rotman M: Long-term
observations of the patterns of failure in patients with
unresectable non-oat cell carcinoma of the lung treated with
definitive radiotherapy. Report by the Radiation Therapy Oncology
Group. Cancer. 59:1874–1881. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jonhnson DH, Einhorn LH, Bartolucci A,
Birch R, Omura G, Perez CA and Greco FA: Thoracic radiotherapy does
not prolong survival in patients with locally advanced,
unresectable non-small cell lung cancer. Ann Intern Med. 113:33–38.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dillman RO, Herndon J, Seagren SL, Eaton
WL Jr and Green MR: Improved survival in stage III non-small-cell
lung cancer: Seven-year follow-up of Cancer and Leukemia Group B
(CALGB) 8433 trial. J Natl Cancer Inst. 88:1210–1215. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schaake-Koning C, van den Bogaert W,
Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A,
Koolen M, Maat B, Nijs A, et al: Effects of concomitant cisplatin
and radiotherapy on inoperable non-small-cell lung cancer. N Engl J
Med. 326:524–530. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sause W, Kolesar P, Taylor S IV, Johnson
D, Livingston R, Komaki R, Emami B, Curran W Jr, Byhardt R, Dar AR
and Turrisi A III: Final results of phase III trial in regionally
advanced unresectable non-small cell lung cancer: Radiation Therapy
Oncology Group, Eastern Cooperative Oncology Group and Southwest
Oncology Group. Chest. 117:358–364. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Clamon G, Herndon J, Eaton W, Rosenman J,
Maurer LH, Cooper MR and Green MR: A feasibility study of extended
chemotherapy for locally advanced non-small cell lung cancer: A
phase II trial of Cancer and Leukemia Group B. Can Invest.
12:273–282. 1994. View Article : Google Scholar
|
|
10
|
Furuse K, Fukuoka M, Kawahara M, Nishikawa
H, Takada Y, Kudoh S, Katagami N and Ariyoshi Y: Phase III study of
concurrent versus sequential thoracic radiotherapy in combination
with mitomycin, vindesine, and cisplatin in unresectable stage III
non-small cell lung cancer. J Clin Oncol. 17:2692–2699.
1999.PubMed/NCBI
|
|
11
|
Curran WJ, Scott CB, Langer CJ, et al:
Long-term benefit is observed in a phase III comparison of
sequential versus concurrent chemo-radiation forpatients with
unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol.
22:6212003.
|
|
12
|
Ulutin HC, Güden M, Oysul K, Sürenkök S
and Pak Y: Split-course radiotherapy with or without concurrent or
sequential chemotherapy in non-small cell lung cancer. Radiat Med.
18:93–96. 2000.PubMed/NCBI
|
|
13
|
Fournel P, Robinet G, Thomas P, Souquet
PJ, Léna H, Vergnenégre A, Delhoume JY, Le Treut J, Silvani JA,
Dansin E, et al: Randomized phase III trial of sequential
chemoradiotherapy compared with concurrent chemoradiotherapy in
locally advanced non-small-cell lung cancer: Groupe
Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de
Pneumo-Cance´rologie NPC 95-01 study. J Clin Oncol. 23:5910–5917.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zatloukal P, Petruzelka L, Zemanova M,
Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P and Pecen L:
Concurrent versus sequential chemoradiotherapy with cisplatin and
vinorelbine in locally advanced non-small cell lung cancer: A
randomized study. Lung Cancer. 46:87–98. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Belderbos J, Uitterhoeve L, van Zandwijk
N, Belderbos H, Rodrigus P, van de Vaart P, Price A, van Walree N,
Legrand C, Dussenne S, et al: Randomised trial of sequential versus
concurrent chemo-radiotherapy in patients with inoperable non-small
cell lung cancer (EORTC 08972–22973). Eur J Cancer. 43:114–121.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aupérin A, Péchoux CL, Rolland E, Curran
WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus
R, et al: Meta-analysis of concomitant versus sequential
radiochemotherapy in locally advanced non-small-cell lung cancer. J
Clin Oncol. 28:2181–2190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aupérin A, Le Péchoux C, Pignon JP, Koning
C, Jeremic B, Clamon G, Einhorn L, Ball D, Trovo MG, Groen HJ, et
al: Concomitant radio-chemotherapy based on platin compounds in
patients with locally advanced non-small cell lung cancer (NSCLC):
A meta-analysis of individual data from 1764 patients. Ann Oncol.
17:473–483. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Davies AM, Chansky K, Lau DH, Leigh BR,
Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ and Gandara DR: SWOG
S9712: Phase II study of consolidation paclitaxel after concurrent
chemoradiation in poor-risk stage III non-small-cell lung cancer:
SWOG S9712. J Clin Oncol. 24:5242–5246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edelman MJ, Chansky K, Gaspar LE, Leigh B,
Weiss GR, Taylor SA, Crowley J, Livingston R and Gandara DR: Phase
II trial of cisplatin/etoposide and concurrent radiotherapy
followed by paclitaxel/carboplatin consolidation for limited
small-cell lung cancer: Southwest Oncology Group 9713. J Clin
Oncol. 22:127–132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakai H, Yoneda S, Kobayashi K, Komagata
H, Kosaihira S, Kazumoto T and Saito Y: Phase II study of bi-weekly
docetaxel and carboplatin with concurrent thoracic radiation
therapy followed by consolidation chemotherapy with docetaxel plus
carboplatin for stage III unresectable non-small cell lung cancer.
Lung Cancer. 43:195–201. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carter DL, Keller AM, Tolley RC, et al: A
randomized phase III trial of combined paclitaxel, carboplatin and
radiation therapy followed by either weekly paclitaxel or
observation in patients with stage III non-small cell lung cancer.
J Clin Oncol. 20(suppl, abstr 7076): 15s2004.
|
|
22
|
Hanna N, Neubauer M, Yiannoutsos C,
McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A,
Fisher W, et al: Phase III study of cisplatin, etoposide, and
concurrent chest radiation with or without consolidation docetaxel
in patients with inoperable stage III non-small-cell lung cancer:
The Hoosier Oncology Group and US Oncology. J Clin Oncol.
26:5755–5760. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Colin P, Jovenin N, Ganem G, et al: Effect
of paclitaxel-carboplatin (PC) consolidation chemotherapy after
weekly PC concurrent chemo-radiotherapy (CCR) for patients with
locally advanced non-small cell lung cancer (LA-NSCLC): 3-year
definitive results of the B001-phase III GERCOR-study. J Clin
Oncol;. 24(suppl, abstr 7112): 18s2006.
|
|
24
|
Huber RM, Engel-Riedel W, Kollmeier J, et
al: GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with
concomitant radiotherapy (RT) followed by either consolidation (C)
with NVBo plus P plus best supportive care (BSC) or BSC alone in
stage (st) III non-small cell lung cancer (NSCLC): Final results of
a phase (ph) III study. J Clin Oncol. 30:452s(suppl, abstr 7001).
2012.
|
|
25
|
Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK,
Lee KC, Chen M, Kim DW, Kim HK, Min YJ, et al: Multinational
randomized phase III trial with or without consolidation
chemotherapy using docetaxel and cisplatin after concurrent
chemoradiation in inoperable stage III non-small-cell lung cancer:
KCSG-LU05-04. J Clin Oncol. 33:2660–2666. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liberati A, Altman DG, Tetzlaff J, Mulrow
C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J
and Moher D: The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate health care
interventions: Explanation and elaboration. PLoS Med.
6:e10001002009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rami-Porta R, Crowley JJ and Goldstraw P:
The revised TNM staging system for lung cancer. Ann Thorac
Cardiovasc Surg. 15:4–9. 2009.PubMed/NCBI
|
|
28
|
Higgins JP and Green S: Cochrane Handbook
for Systematic Reviews of Interventions. Version 5.1.0 (updated
March 2011). The Cochrane Collaboration. 2011.simplewww.Cochrane-handbook.org
|
|
29
|
Jadad A, Moore RA, Carroll D, Jenkinson C,
Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of
reports of randomized clinical trials: Is blinding necessary?
Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Montori V and Guyatt GH:
Intention-to-treat principle. CMAJ. 165:1339–1341. 2001.PubMed/NCBI
|
|
31
|
Fergusson D, Aaron SD, Guyatt G and Hébert
P: Post-randomisation exclusions: The intention to treat principle
and excluding patients from analysis. BMJ. 325:652–654. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu D, Zheng X, Chen J, Liu G, Xu Y, Shen
Y, Xie L, Zhao W, Jiang G and Fan M: Induction chemotherapy with
cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy
and concurrent cetuximab, vinorelbine-cisplatin in patients with
unresectable stage III non-small cell lung cancer. Lung Cancer.
89:249–254. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vokes EE, Herndon JE II, Kelley MJ,
Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W
and Green MR: Cancer and Leukemia Group B: Induction chemotherapy
followed by chemoradiotherapy compared with chemoradiotherapy alone
for regionally advanced unresectable stage III Non-small-cell lung
cancer: Cancer and Leukemia Group B. J Clin Oncol. 25:1698–1704.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Divers SG, Spencer SA, Carey D, Busby EM,
Hyatt MD and Robert F: Phase I/IIa study of cisplatin and
gemcitabine as induction chemotherapy followed by concurrent
chemoradiotherapy with gemcitabine and paclitaxel for locally
advanced non-small-cell lung cancer. J Clin Oncol. 23:6664–6673.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tsujino K, Kurata T, Yamamoto S, Kawaguchi
T, Kubo A, Isa S, Hasegawa Y, Ou SH, Takada M and Ando M: Is
consolidation chemotherapy after concurrent chemo-radiotherapy
beneficial for patients with locally advanced non-small-cell lung
cancer? A pooled analysis of the literature. J Thorac Oncol.
8:1181–1189. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsujino K, Kurata T, Kawaquchi T, Kubo A,
Takada M and Ando M: Role of consolidation chemotherapy after
concurrent chemo-radiotherapy in locally advanced non-small-cell
lung cancer. J Thorac Oncol. 9:e7–e8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kelly K, Chansky K, Gaspar LE, Albain KS,
Jett J, Ung YC, Lau DH, Crowley JJ and Gandara DR: Phase III trial
of maintenance gefitinib or placebo after concurrent
chemoradiotherapy and docetaxel consolidation in inoperable stage
III non-small-cell lung cancer: SWOG S0023. J Clin Oncol.
26:2450–2456. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schild SE, Stella PJ, Geyer SM, Bonner JA,
McGinnis WL, Mailliard JA, Brindle J, Jatoi A and Jett JR: North
Central Cancer Treatment Group: The outcome of combined-modality
therapy for stage III non-small-cell lung cancer in the elderly. J
Clin Oncol. 21:3201–3206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jalal SI, Riggs HD, Melnyk A, Richards D,
Agarwala A, Neubauer M, Ansari R, Govindan R, Bruetman D, Fisher W,
et al: Updated survival and outcomes for older adults with
inoperable stage III non-small-cell lung cancer treated with
cisplatin, etoposide, and concurrent chest radiation with or
without consolidation docetaxel: Analysis of a phase III trial from
the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol.
23:1730–1738. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Davidoff AJ, Gardner JF, Seal B and
Edelman MJ: Population-based estimates of survival benefit
associated with combined modality therapy in elderly patients with
locally advanced non-small cell lung cancer. J Thorac Oncol.
6:934–941. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bria E, Cuppone F, Ciccarese M, Nisticò C,
Facciolo F, Milella M, Izzo F, Terzoli E, Cognetti F and
Giannarelli D: Weekly docetaxel as second line chemotherapy for
advanced non-small-cell lung cancer: Meta-analysis of randomized
trials. Cancer Treat Rev. 32:583–587. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Camps C, Massuti B, Jiménez A, Maestu I,
Gómez RG, Isla D, González JL, Almenar D, Blasco A, Rosell R, et
al: Randomized phase III study of 3-weekly versus weekly docetaxel
in pretreated advanced non-small-cell lung cancer: A Spanish Lung
Cancer Group trial. Ann Oncol. 17:467–472. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gridelli C, Gallo C, Di Maio M, Barletta
E, Illiano A, Maione P, Salvagni S, Piantedosi FV, Palazzolo G,
Caffo O, et al: A randomised clinical trial of two docetaxel
regimens (weekly vs 3 week) in the second-line treatment of
non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer.
91:1996–2004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Schuette W, Nagel S, Blankenburg T,
Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H,
von Weikersthal LF, Raghavachar A, et al: Phase III study of
second-line chemotherapy for advanced non-small-cell lung cancer
with weekly compared with 3-weekly docetaxel. J Clin Oncol.
23:8389–8395. 2005. View Article : Google Scholar : PubMed/NCBI
|
